Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.69 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | CA9 | Q16790 | 3/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.43 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003913 | 0.89 | POLB (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15495794 | 0.85 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9322998 | 0.84 | THRB (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9393216 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| Methyl 2-Hydroxy-6-Methoxybenzoate SCHEMBL1339134 | 0.84 | CA1 (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7094792 | 0.83 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1519936 | 0.83 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11282176 | 0.83 | KDM4E (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4644099 | 0.82 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19335220 | 0.82 | CA12 (0.62) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555519-B2 | Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| EP-1268503-A1 | O-GLUCOSYLATED BENZAMIDE SGLT2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020052326-A1 | O-glucosylated benzamide SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-02 | — | — | US | disclosed |
| WO-2001074835-A1 | O-GLUCOSYLATED BENZAMIDE SGLT2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052326-A1 | O-glucosylated benzamide SGLT2 inhibitors and method | SLC5A2, SLC5A1, SLC2A1 | CA12 2717/4885CA1 4114/4885CA2 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.